Pharma Stocks Jump by Up to 8% in Today’s Trading Session; Here’s Why

Synopsis: Pharma stocks rallied as the Nifty Pharma Index hit a fresh 52-week high, supported by rising GLP-1 demand, strong export prospects, and a positive industry outlook, with several pharma stocks gaining up to 8%.

Pharma stocks have been gaining attention after showing strong performance in the stock market. The sector has performed better than the overall market in recent days because investors are expecting better growth in the coming years. Higher demand for medicines, growing export opportunities, and new business chances are supporting positive sentiment. Experts believe the sector could continue to grow as Indian manufacturers increase production and expand into global markets.

Nifty Pharma Index Hits a New High

The Nifty Pharma Index climbed nearly 2 percent to touch a fresh 52-week high of 25,463.70 on the NSE. During the same trading session, the benchmark Nifty 50 slipped 0.38 percent, showing the pharma sector’s strong performance. Over the last seven trading sessions, the Nifty Pharma Index has risen 5.4 percent, while the Nifty 50 has slipped 0.87 percent.

The strong rally reflects growing investor confidence in pharma stocks. Market experts believe the sector is benefiting from improving business conditions and better earnings expectations. The broad-based buying across pharma stocks also indicates that investors are optimistic about the industry’s future growth.

Strong Demand Supports Pharma Stocks

Pharma stocks moved higher as investors became positive about the future of the industry. One of the main reasons is the rising demand for GLP-1 medicines, which are used to treat diabetes and obesity. As patents on some popular medicines expire, Indian manufacturers are expected to produce more affordable versions for global markets.

At the same time, exports are improving with strong demand from Africa, West Asia, and Latin America. Although approvals for some regulated markets still take time, companies are increasing their manufacturing capacity. This has created confidence that the pharma sector will continue to see healthy growth in the coming years.

Long-Term Growth Looks Positive

The long-term outlook for pharma stocks remains strong because of several growth drivers. Industry experts believe that many high-value biologic medicines will lose patent protection over the next few years. This will create a big opportunity for biosimilars, which are lower-cost versions of these medicines, helping Indian manufacturers expand their global presence.

The industry is also expected to benefit from stable demand for generic medicines, increasing use of artificial intelligence in drug development, and changes in global supply chains. Rising exports and stronger manufacturing capabilities are further supporting growth. With these factors in place, pharma stocks are expected to remain an important sector for investors to watch.

Defensive Nature of Pharma

Pharma stocks are often called a defensive sector because people need medicines and healthcare services in all types of market conditions. Demand for medicines usually remains steady even during economic slowdowns, helping pharma companies maintain stable sales and earnings. This makes pharma stocks less affected by market volatility compared to many other sectors, making them attractive for long-term investors. Here are a few pharma stocks that surged up to 8 percent in today’s trading session.

Dr Reddy’s Laboratories Limited

With a market capitalization of Rs. 1,15,071.37 crores, the share of Dr Reddy’s Laboratories Limited has reached an intraday high of Rs. 1,414.40 per equity share, rising nearly 4.77 percent from its previous day’s close price of Rs. 1,350. Since then, the stock has retreated and is currently trading at Rs. 1,378.70 per equity share. 

Dr. Reddy’s Laboratories is a global pharmaceutical company headquartered in Hyderabad, India, focused on developing, manufacturing, and marketing medicines across a wide range of therapeutic areas. Founded in 1984 by Kallam Anji Reddy, it has grown into one of India’s largest drugmakers, with operations spanning dozens of countries and a portfolio that includes generics, biosimilars, active pharmaceutical ingredients (APIs), vaccines, and consumer healthcare products.

Ajanta Pharma Limited

With a market capitalization of Rs. 42,721.74 crores, the share of Ajanta Pharma Limited has reached an intraday high of Rs. 3,429 per equity share, rising nearly 7.90 percent from its previous day’s close price of Rs. 3,177.90. Since then, the stock has retreated and is currently trading at Rs. 3,419.50 per equity share. 

is an Indian specialty pharmaceutical company that develops, manufactures, and markets branded generic medicines and generic pharmaceutical products. Founded in 1973 and headquartered in Mumbai, it has built a significant international presence, supplying medicines across more than 30 countries while maintaining leadership in several therapeutic segments through first-to-market products.

Ipca Laboratories Limited

With a market capitalization of Rs. 41,980.60 crores, the share of Ipca Laboratories Limited has reached an intraday high of Rs. 1,664.90 per equity share, rising nearly 2.92 percent from its previous day’s close price of Rs. 1,617.70. Since then, the stock has retreated and is currently trading at Rs. 1,655.00 per equity share. 

Ipca Laboratories is an Indian multinational pharmaceutical company headquartered in Mumbai that develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs). Founded in 1949, it has grown into one of India’s significant pharmaceutical manufacturers, with a strong presence in both domestic and international markets and operations spanning more than 100 countries. 

Cipla Limited

With a market capitalization of Rs. 1,17,945.42 crores, the share of Cipla Limited has reached an intraday high of Rs. 1,490.00 per equity share, rising nearly 3.45 percent from its previous day’s close price of Rs. 1,440.30. Since then, the stock has retreated and is currently trading at Rs. 1,460.00 per equity share. 

Cipla is an Indian multinational pharmaceutical company that develops, manufactures, and markets medicines across a wide range of therapeutic areas. It is one of India’s largest drug makers and is widely recognized for expanding access to affordable medicines, particularly in respiratory care and treatments for infectious diseases.

Lupin Limited

With a market capitalization of Rs. 1,09,379.17 crores, the share of Lupin Limited has reached an intraday high of Rs. 2,404.00 per equity share, rising nearly 2.64 percent from its previous day’s close price of Rs. 2,342.15. Since then, the stock has retreated and is currently trading at Rs. 2,392.20 per equity share. 

Lupin is an Indian multinational pharmaceutical company headquartered in Mumbai, India. Founded in 1968, it has grown from a small healthcare venture into one of India’s largest pharmaceutical manufacturers, with operations spanning more than 100 markets and a strong presence in generics, specialty medicines, biosimilars, and active pharmaceutical ingredients (APIs).

Laurus Labs Limited

With a market capitalization of Rs. 80,171.40 crores, the share of Laurus Labs Limited has reached an intraday high of Rs. 1,488.95 per equity share, rising nearly 2.64 percent from its previous day’s close price of Rs. 1,450.60. Since then, the stock has retreated and is currently trading at Rs. 1,485.05 per equity share. 

Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad, focused on active pharmaceutical ingredients (APIs), generic formulations, and contract development and manufacturing (CDMO) services. Founded in 2005 by Satyanarayana Chava, it has grown into one of India’s leading pharmaceutical manufacturers with a significant global presence and a strong position in antiretroviral drug ingredients and outsourced pharmaceutical manufacturing.

Torrent Pharmaceuticals Limited

With a market capitalization of Rs. 1,56,690.56 crores, the share of Torrent Pharmaceuticals Limited has reached an intraday high of Rs. 4,658.00 per equity share, rising nearly 3.10 percent from its previous day’s close price of Rs. 4,518.15. Since then, the stock has retreated and is currently trading at Rs. 4,629.90 per equity share. 

Torrent Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, and the flagship pharmaceutical business of the Torrent Group. Founded in 1959, it has grown into one of India’s leading drug manufacturers with operations spanning more than 50 countries and a strong presence in branded generics and specialty therapies.

Sun Pharmaceutical Industries Limited

With a market capitalization of Rs. 4,49,180.91 crores, the share of Sun Pharmaceutical Industries Limited has reached an intraday high of Rs. 1,896.75 per equity share, rising nearly 1.86 percent from its previous day’s close price of Rs. 1,862.15. Since then, the stock has retreated and is currently trading at Rs. 1,876 per equity share. 

Sun Pharmaceutical Industries (commonly known as Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. Founded in 1983 by Dilip Shanghvi, it has grown into India’s largest pharmaceutical company and one of the world’s leading specialty generic drug manufacturers, with products sold in more than 100 countries.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stocks Jump by Up to 8% in Today’s Trading Session; Here’s Why appeared first on Trade Brains.